CMV-GFP AAV (Serotype AAV-BI30)

AAV-BI30 is an adeno-associated virus (AAV) vector that fully demonstrates the significant advantages of viral vector technology in gene delivery. As a serotype variant, BI30 exhibits excellent tropism for specific target tissues, enabling efficient transduction while minimizing off-target effects. AAV itself possesses excellent safety, is non-pathogenic, and can achieve long-term transgene expression without integrating into the host genome—a key characteristic that significantly reduces the risk of mutagenesis compared to other viral vectors. BI30''s engineered capsid protein enhances its ability to evade neutralizing antibodies, significantly improving its transduction efficiency in preclinical models and potential clinical applications. With its optimized promoter system and a payload capacity of up to 4.7 kb, this vector enables sustained, high-level gene expression while maintaining low immunogenicity, making it particularly suitable for chronic diseases requiring continuous production of therapeutic proteins.

The therapeutic applications of AAV-BI30 span multiple disease areas, with particularly promising prospects in the treatment of monogenic and degenerative diseases. In neurology, its enhanced blood-brain barrier penetration makes it an ideal choice for targeting central nervous system diseases such as Parkinson''s disease, Huntington''s disease, and various lysosomal storage disorders. In ophthalmology, its tropism for the retina makes it suitable for treating inherited retinal dystrophies, such as Leber congenital amaurosis and retinitis pigmentosa. The vector''s muscle-targeting capabilities also show great potential in treating neuromuscular diseases such as Duchenne muscular dystrophy and spinal muscular atrophy. Beyond genetic diseases, AAV-BI30 is also an excellent platform for delivering therapeutic antibodies or CRISPR components in gene editing applications.